016 证券代码：605186 证券简称：健麾信息 公告编号：2023- 上海健麾信息技术股份有限公司 2022 年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利 0.09 元 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2023/8/24 | － | 2023/8/25 | 2023/8/25 | 差异化分红送转： 否 本次利润分配方案经公司 2023 年 6 月 29 日的 2022 年年度股东大会审议通过。具体内容详见 公司于 2023 年 6 月 30 日刊登在《上海证券报》《中国证券报》《证券时报》《证券日报》及 上海证券交易所网站（www.sse.com.cn）的《2022 年年度股东大会决议公告》（公告编号：2023- 014）。 二、 分配方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 ...

证券代码：605186 证券简称：健麾信息 公告编号：2023-012 上海健麾信息技术股份有限公司 关于召开 2022 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： https://roadshow.sseinfo.com/） 上海健麾信息技术股份有限公司（以下简称"公司"）已于 2023 年 4 月 29 日发布公司 2022 年度报告，为便于广大投资者更全面深入 地了解公司 2022 年度经营成果、财务状况，公司计划于 2023 年 06 月 15 日 下午 15:00-16:00 举行 2022 年度业绩说明会，就投资者关 心的问题进行交流。 一、 说明会类型 会议召开时间：2023 年 06 月 15 日(星期四) 下午 15:00-16:00 会议召开地点：上海证券交易所上证路演中心（网址： 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 06 月 08 日(星期四) 至 06 月 14 日(星期 三)16:00 前登录上证路演中心网站首页点击"提问预征集"栏目 ...

Financial Performance - The net profit attributable to the parent company's shareholders for 2022 is CNY 115,681,544.43, with a total distributable profit of CNY 217,201,772.33 as of December 31, 2022[5]. - The proposed cash dividend is CNY 0.90 per 10 shares (including tax), totaling CNY 12,240,000.00, which represents 10.58% of the net profit attributable to the parent company[5]. - The company's operating revenue for 2022 was CNY 322,359,785.92, a decrease of 34.18% compared to CNY 489,755,358.90 in 2021[25]. - The net profit attributable to shareholders for 2022 was CNY 115,681,544.43, down 1.65% from CNY 117,618,137.99 in 2021[25]. - The cash flow from operating activities showed a net outflow of CNY -37,261,950.98 in 2022, a decline of 169.22% compared to CNY 53,827,755.74 in 2021[25]. - The basic earnings per share for 2022 was CNY 0.85, a decrease of 1.16% from CNY 0.86 in 2021[27]. - The total assets at the end of 2022 were CNY 1,198,844,121.40, an increase of 6.13% from CNY 1,129,566,326.94 at the end of 2021[26]. - The company reported a decrease in the weighted average return on equity to 12.11% in 2022 from 13.64% in 2021, a reduction of 1.53 percentage points[27]. - The net profit after deducting non-recurring gains and losses was CNY 96,730,991.02, down 10.31% from CNY 107,847,786.04 in 2021[25]. - The total net assets attributable to shareholders increased to CNY 1,004,966,459.25 at the end of 2022, up 11.47% from CNY 901,524,914.82 at the end of 2021[25]. Business Operations and Strategy - The company experienced a significant decline in revenue due to external factors affecting the supply-demand relationship in the industry[27]. - The company secured a CNY 69 million contract for the "Zhongxiang Smart Medical Integrated Project," expanding its "To-G" bulk model business[36]. - The company established joint ventures in various fields, including unmanned medicine dispensing machines and automated logistics, indicating a strategic expansion into new business areas[37]. - A joint venture was signed with Ajlan & Bros Information Technology Company to establish a new company in Riyadh, Saudi Arabia, aiming to enhance the company's presence in the Middle East and North Africa markets[38]. - The company focused on improving operational capabilities and management efficiency, implementing strict budget controls and lean production management[39]. - The company is actively pursuing opportunities in the smart pharmaceutical management sector, driven by increasing demands for efficiency and quality in drug dispensing[44]. - The establishment of centralized intravenous medication preparation centers is creating further development space for high-tech automation in the pharmaceutical management field[45]. - The company is currently developing new products such as hospital logistics robots and automated drug dispensing machines to enhance service offerings[55]. - The company’s projects involve a comprehensive approach including hardware and software integration, system design, and ongoing maintenance services[57]. Market Trends and Growth Potential - The global market for automated pharmacy systems is growing, with the average adoption rate in developed countries around 30% as of 2013[43]. - In the U.S., 97% of hospitals were equipped with automated dispensing devices by the end of 2014, highlighting the trend towards automation in healthcare[43]. - The market for retail pharmacies is expected to grow due to the rise of internet healthcare and automation, with a focus on O2O models[48]. - The company is focusing on expanding its market presence in Hubei and surrounding provinces, leveraging synergies with its existing products[110]. - The market penetration rate of automated pharmacy equipment in China is expected to increase significantly due to rising healthcare investments and policy support, with a projected growth in the industry[111]. - By 2023, the penetration rates for automated pharmacy equipment in various cities are forecasted to rise: Beijing from 4% to 45%, Shenzhen from 6% to 57%, Suzhou from 30% to 65%, and Shanghai from 5% to 48%[112]. Research and Development - The total R&D expenditure amounted to CNY 22,415,836.21, representing 6.95% of operating income[85]. - The company has 70 R&D personnel, accounting for 19.23% of the total workforce[86]. - The company aims to enhance its R&D capabilities and product development, focusing on market-oriented strategies and leveraging technologies like machine vision and deep learning[116]. - A talent development plan will be implemented to strengthen the R&D team and attract experienced professionals to support the company's growth[121]. Governance and Compliance - The company is committed to ensuring the authenticity, accuracy, and completeness of the annual report[3]. - The audit report issued by the accounting firm is a standard unqualified opinion[4]. - The internal control system was evaluated as effective, with no significant deficiencies found in financial reporting controls[165]. - The company has established specialized committees under the board, including the Audit Committee, Nomination Committee, Compensation and Assessment Committee, and Strategic Committee[147]. - The company has no reported penalties from securities regulatory agencies in the past three years[145]. - The company has maintained a stable leadership structure, with key executives serving since 2017, ensuring continuity in management and strategic direction[137]. Shareholder Relations and Commitments - The company commits to not transferring or entrusting the management of its shares for 36 months post-IPO, with a lock-up extension of 6 months if stock prices fall below the IPO price for 20 consecutive trading days within the first 6 months[180]. - The company has reiterated its commitment to adhere to all relevant laws and regulations regarding shareholding and transfer practices[178]. - The company will ensure compliance with all relevant laws and regulations regarding share repurchase and management[187]. - Major shareholders, including the controlling shareholders, have committed to fulfilling all obligations related to public commitments made during the IPO process[190]. - The company guarantees that the prospectus for the IPO does not contain false records or misleading statements, and it will bear legal responsibility for its accuracy[193].

Financial Performance - The company's operating revenue for Q1 2023 was ¥61,275,234.89, representing a year-on-year increase of 35.03%[5] - The net profit attributable to shareholders for the same period was ¥9,943,347.23, reflecting a growth of 40.98% compared to the previous year[5] - The basic earnings per share for Q1 2023 was ¥0.07, an increase of 40.00% year-on-year[6] - The weighted average return on equity rose to 0.98%, an increase of 0.20 percentage points from the previous year[6] - The company reported a significant increase in sales revenue from services, contributing to the overall revenue growth[23] - The financial outlook remains positive, with expectations for continued revenue growth and improved profitability in the upcoming quarters[24] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,198,379,220.88, showing a slight decrease of 0.04% compared to the end of the previous year[6] - As of March 31, 2023, the total assets of the company amounted to CNY 1,198,379,220.88, slightly down from CNY 1,198,844,121.40 at the end of 2022[17] - The company's current assets totaled CNY 776,059,761.70, a decrease from CNY 829,966,363.51 at the end of 2022, indicating a decline of approximately 6.5%[18] - The company's non-current assets increased to CNY 422,319,459.18 from CNY 368,877,757.89, reflecting an increase of about 14.4%[18] - The total liabilities of the company were CNY 106,860,248.96, down from CNY 115,583,848.53, representing a decrease of approximately 7.4%[19] - The company's cash and cash equivalents were CNY 303,158,377.31, down from CNY 366,273,999.90, indicating a decline of about 17.2%[17] Cash Flow - The net cash flow from operating activities was negative at -¥46,915,420.31, indicating a significant cash outflow[5] - Cash flow from operating activities showed a net outflow of ¥46,915,420.31, an improvement from a net outflow of ¥60,500,250.05 in Q1 2022[27] - The net cash flow from investing activities was -$40,960,093.79, an improvement from -$47,339,470.31 in the previous period[28] - The net cash flow from financing activities was $24,735,729.17, with cash inflow from borrowings amounting to $25,000,000.00[28] - The total cash and cash equivalents at the end of the period decreased to $270,988,348.82 from $360,524,063.75, reflecting a net decrease of $63,115,622.59[28] Expenses - The company reported a 75.28% increase in operating costs, which aligned with the revenue growth during the period[11] - Operating costs amounted to ¥51,831,889.26, up from ¥34,700,305.33, reflecting a significant increase in expenses[23] - Research and development expenses were ¥5,567,972.60, slightly down from ¥5,569,046.07 in the previous year[24] Receivables and Inventory - The company experienced a 68.21% increase in other receivables, attributed to an increase in land deposit guarantees[10] - The company's inventory increased to CNY 91,289,460.26 from CNY 74,023,447.28, reflecting an increase of about 23.4%[18] - Accounts receivable decreased to CNY 301,081,720.73 from CNY 332,887,498.88, a reduction of approximately 9.5%[18] - The company’s other receivables increased to CNY 18,214,695.02 from CNY 10,828,485.10, an increase of approximately 68.5%[18] Borrowings - Short-term borrowings increased by 100.00% during the reporting period, indicating a rise in bank short-term loans[11] - The company reported a decrease in short-term borrowings to CNY 25,000,000.00, indicating a reduction in leverage[19] Accounting Standards - The company has not adopted new accounting standards or interpretations that would affect the financial statements for the current year[28]

Group 1: Company Performance and Recovery - The company resumed full operations on June 1, 2022, after being approved as a second batch of companies for resumption in Shanghai [3] - The overall business performance remained stable despite the impact of the COVID-19 pandemic [3] - The company has implemented refined management strategies to adapt to the pandemic situation [4] Group 2: Market Position and Client Base - The company has implemented intelligent drug management projects in over 700 hospitals across 29 provinces, with more than half of the top 100 hospitals in China as clients [3] - The company focuses on the pharmaceutical intelligent management sector and has a strong market presence in economically developed coastal regions, particularly in first and second-tier cities [4] Group 3: Future Strategy and Business Development - In 2022, the company aims to enhance product development and market expansion while optimizing production and management efficiency [4] - The company plans to explore the "to-G" market and increase its market share in the retail pharmaceutical sector [4] - The company has a strategic layout for the retail market and aims to penetrate lower-tier medical service institutions [4]

公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2022 年第三季度报告 证券代码：605186 证券简称：健麾信息 上海健麾信息技术股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 | 项目 | 本报告期 | 本报告期比 上年同期增 | 年初至报告期末 | 年初至报告期 末比上年同期 | | --- | --- | --- | --- | --- | | | | 减变动幅度 | | 增减变动幅度 | | | | (%) | | (%) | | 营业收入 | 113,472,020.66 | -14.92 | 275,357,637.72 | -3.4 | | 归属于上市公司股东 ...

Financial Performance - The company's operating revenue for the first half of 2022 was ¥161,885,617.06, representing a 6.74% increase compared to ¥151,665,389.91 in the same period last year[20]. - The net profit attributable to shareholders of the listed company was ¥54,360,227.05, up 5.02% from ¥51,762,534.45 in the previous year[20]. - The net profit after deducting non-recurring gains and losses was ¥51,610,072.47, which is an increase of 11.20% compared to ¥46,411,777.07 in the same period last year[20]. - The basic earnings per share was CNY 0.40, up 5.26% from CNY 0.38 in the same period last year[21]. - The diluted earnings per share also stood at CNY 0.40, reflecting a 5.26% increase year-on-year[21]. - The weighted average return on equity was 5.85%, down 0.32 percentage points from the previous year[21]. - The weighted average return on assets after deducting non-recurring gains and losses increased by 0.03 percentage points to 5.56%[21]. - The company reported a significant increase in revenue for the first half of 2022, achieving a total of 1.5 billion RMB, representing a year-over-year growth of 25%[97]. - The company recorded a comprehensive income of CNY 54,360,227.05 for the first half of 2022, indicating positive performance in its financial results[171]. Cash Flow and Assets - The net cash flow from operating activities decreased by 65.81%, amounting to ¥9,395,849.83, down from ¥27,478,194.54 in the previous year[20]. - The company's cash and cash equivalents decreased by 11.57% to 414.65 million yuan compared to the previous year[63]. - The company's inventory decreased by 20.90% to 48.03 million yuan compared to the previous year[63]. - The total current assets decreased to ¥799,579,832.93 from ¥850,687,666.75, reflecting a decline of approximately 6%[148]. - Cash and cash equivalents decreased to ¥414,646,712.82 from ¥468,916,999.82, a reduction of about 11.5%[148]. - The company reported a net decrease in cash and cash equivalents of CNY -56,488,152.25, an improvement from CNY -234,215,319.20 in the prior year[167]. Business Operations and Strategy - The company faced challenges due to the COVID-19 pandemic, affecting project timelines and operational cash flow[21]. - The company is currently developing new products such as hospital logistics robots and automated drug dispensing machines to enhance service offerings[41]. - The company aims to strengthen its market position as public hospitals' roles are expected to be reinforced by government policies[35]. - The retail pharmacy market share is anticipated to increase due to the rapid development of internet healthcare and automation in drug management[35]. - The company is focusing on building an industrial ecosystem and expanding into related business areas, including automation in wards and operating rooms[56]. Research and Development - Research and development expenses amounted to 10.38 million yuan, representing a growth of 5.72% compared to the previous year[57]. - The company has established a comprehensive R&D system with nearly 20 years of experience in intelligent drug management, enhancing its innovation capabilities[45]. - The company is investing 200 million RMB in R&D for new technologies aimed at improving operational efficiency and product quality[103]. Shareholder Commitments and Governance - The company commits to not transferring or entrusting the management of its shares for 36 months post-IPO, with an automatic extension of 6 months if stock prices fall below the IPO price for 20 consecutive trading days within the first 6 months[104]. - Major shareholders, including Ningbo Hydra, have pledged to hold 1,020,000 shares without transfer or management delegation for 36 months post-IPO[105]. - The controlling shareholder, Dai Jianwei, plans to support the company's development and will not reduce shareholdings below the IPO price for two years post-lock-up, with annual reductions capped at 25% of their holdings[107]. - The company will implement stock price stabilization measures if the stock price falls below the audited net asset value per share for 20 consecutive trading days within three years post-IPO[109]. - The company guarantees that the prospectus for the IPO does not contain false statements or omissions, and will compensate investors for losses if such issues are identified[117]. Market Position and Expansion - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2023[101]. - A strategic acquisition of a local competitor is anticipated to enhance the company's product offerings and increase market penetration[102]. - The company has provided intelligent drug management projects for over 700 medical institutions, including top hospitals in China[36]. Financial Health and Liabilities - Total liabilities decreased to ¥94,769,032.15 from ¥154,027,955.51, a significant reduction of about 38.5%[150]. - The company reported a significant reduction in tax payables by 51.60% to CNY 17.24 million, attributed to early payments of VAT and corporate income tax[65]. - The company's accounts payable decreased by 59.72% to CNY 13.09 million, mainly due to the settlement of large project payments[65]. Compliance and Legal Matters - The company has not engaged in any significant litigation or arbitration matters during the reporting period[126]. - There were no non-operating fund occupations by controlling shareholders or related parties during the reporting period[126]. - The company has not faced any penalties or corrective actions related to legal violations during the reporting period[126].

Financial Performance - The net profit attributable to the parent company's shareholders for 2021 was CNY 117,618,137.99, with a proposed cash dividend of CNY 0.9 per 10 shares, totaling CNY 12,240,000.00, which represents 10.41% of the net profit[5]. - The company's operating revenue for 2021 was CNY 489,755,358.90, representing a 70.76% increase compared to CNY 286,806,988.65 in 2020[21]. - Net profit attributable to shareholders for 2021 was CNY 117,618,137.99, a 22.85% increase from CNY 95,739,268.21 in 2020[21]. - The net profit after deducting non-recurring gains and losses was CNY 107,847,786.04, up 22.28% from CNY 88,194,212.79 in 2020[21]. - The company's total assets increased by 13.25% to CNY 1,129,566,326.94 at the end of 2021, compared to CNY 997,404,072.75 at the end of 2020[21]. - The weighted average return on equity decreased to 13.64% in 2021 from 29.01% in 2020, a decline of 15.37 percentage points[22]. - The basic earnings per share for 2021 was CNY 0.86, a decrease of 8.51% from CNY 0.94 in 2020[22]. - The company reported a net asset attributable to shareholders of CNY 901,524,914.82 at the end of 2021, a 10.87% increase from CNY 813,146,776.83 at the end of 2020[21]. Dividends and Profit Distribution - The company plans to maintain the total distribution amount unchanged, adjusting the per-share distribution ratio if there are changes in the total share capital before the dividend record date[5]. - The company has not proposed any capital reserve fund transfers to increase share capital or bonus shares for this profit distribution[5]. - The company plans to distribute a cash dividend of 0.9 yuan per 10 shares, totaling 12,240,000 yuan, which represents 10.41% of the net profit attributable to shareholders[160]. - The cash dividend policy aims to protect minority shareholders' rights and is based on the company's strategic management goals[159]. Risks and Compliance - The company has not disclosed any significant risks that could affect its future development in the report[8]. - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties[7]. - The company has not violated decision-making procedures for providing guarantees[8]. - The company has not faced any penalties from securities regulatory authorities in the past three years[142]. - The company has no reported risks or dissenting opinions from the supervisory board during the reporting period[153]. Research and Development - Research and development expenses amounted to 23.20 million yuan, reflecting a growth of 41.93% year-on-year[32]. - The total R&D investment for the period is CNY 23,197,509.95, representing 4.74% of the operating revenue[85]. - The number of R&D personnel is 64, making up 19.63% of the total workforce[86]. - The company emphasizes the importance of R&D for maintaining competitive advantage in the pharmaceutical automation sector[54]. Market Expansion and Strategy - The company is actively expanding its market presence in central and western regions of China, targeting lower-tier medical institutions[36]. - The company aims to optimize its sales strategy and expand its distribution network, focusing on the growing market opportunities in China's healthcare infrastructure, particularly in second and third-tier cities[112]. - The company plans to capture a larger share of the retail pharmacy market by collaborating with leading clients and developing targeted products for the retail environment, enhancing brand penetration and overall revenue[113]. - The company is committed to expanding its dealer and agent network to strengthen its leading position in the domestic intelligent pharmaceutical management sector[110]. Governance and Management - The company has established four specialized committees under the board to ensure scientific and standardized decision-making[128]. - The company strictly adhered to legal regulations and internal control systems to maintain governance standards and protect shareholder rights[129]. - The company has a performance assessment system in place to align the interests of senior management with the company's long-term development[129]. - The company has maintained independence from its controlling shareholders in terms of personnel, assets, finance, and operations[129]. - The company has a structured remuneration decision-making process involving the compensation and assessment committee of the board[140]. Operational Performance - The company has implemented intelligent drug management projects in over 700 hospitals across 29 provinces, enhancing its brand advantage[64]. - The company successfully secured a large order for mobile medical service vehicles from the Hubei Provincial Health Commission, contributing significantly to revenue growth[23]. - The company experienced a significant increase in maintenance and service revenue due to business expansion[23]. - The company has a well-established after-sales service network covering major cities, ensuring rapid response to customer needs[66]. Inventory and Accounts Receivable - Inventory increased to 60.72 million yuan, a significant rise of 146.57% from the beginning of the period[31]. - Accounts receivable increased by 38.52% to ¥286,994,522.69, up from ¥207,185,026.24 in the previous period, primarily due to the impact of COVID-19 on medical institutions and pharmaceutical distribution companies[91]. - The company's inventory value at the end of the reporting period was 60.72 million yuan, which constitutes 7.14% of current assets, posing risks related to acceptance and impairment of inventory[122]. Shareholder Commitments and Lock-up Period - The company commits to a maximum of 25% share transfer annually after the lock-up period ends, and no transfers will occur within six months post-departure[188]. - The company will adhere to regulations regarding shareholding changes and lock-up periods as per relevant laws and regulations[182]. - The company’s major shareholders include Hanyu Pharmaceutical and Jianqu Investment, which also committed to similar lock-up agreements[186]. - The company will ensure that any share reduction attempts post-lock-up will not be below the IPO price adjusted for any corporate actions[185]. Social Responsibility - The company donated a total of 100,000 yuan to support poverty alleviation efforts in targeted regions, contributing to rural revitalization[176]. - The company implemented measures to ensure the normal operation of its products in hospitals during the pandemic, enhancing safety with contactless self-service medication dispensing devices[172].

Financial Performance - The company's operating revenue for Q1 2022 was ¥45,380,407.33, representing an increase of 11.19% compared to the same period last year[5]. - The net profit attributable to shareholders for Q1 2022 was ¥7,052,836.21, reflecting a growth of 10.65% year-over-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥7,012,578.93, which is an increase of 15.54% compared to the previous year[5]. - Total operating revenue for Q1 2022 was CNY 45,380,407.33, an increase of 11.5% compared to CNY 40,811,846.52 in Q1 2021[20]. - Net profit for Q1 2022 reached CNY 8,151,632.47, up 10.4% from CNY 7,378,978.29 in Q1 2021[21]. - Total operating costs for Q1 2022 were CNY 34,700,305.33, an increase of 10.4% from CNY 31,247,677.80 in Q1 2021[20]. Cash Flow and Assets - The company's cash flow from operating activities for Q1 2022 was negative at -¥60,500,250.05, indicating a significant cash outflow[5]. - Cash flow from operating activities showed a net outflow of CNY 60,500,250.05, worsening from a net outflow of CNY 51,838,262.91 in Q1 2021[25]. - Cash inflow from investment activities was CNY 50,044,046.16, while cash outflow was CNY 97,383,516.47, resulting in a net cash outflow of CNY 47,339,470.31[25]. - The total assets at the end of Q1 2022 were ¥1,064,942,116.69, a decrease of 5.72% from the end of the previous year[6]. - As of March 31, 2022, the company's total assets amounted to ¥1,064,942,116.69, a decrease from ¥1,129,566,326.94 as of December 31, 2021, reflecting a decline of approximately 5.7%[17]. - The company's current assets totaled ¥753,502,166.74, down from ¥850,687,666.75, indicating a decrease of about 11.4%[18]. - Cash and cash equivalents were reported at ¥361,024,063.75, a decrease of 23.0% from ¥468,916,999.82 at the end of 2021[17]. - The net increase in cash and cash equivalents for the period was -$107,892,936.07[26]. - The beginning balance of cash and cash equivalents was $468,416,999.82[26]. - The ending balance of cash and cash equivalents was $360,524,063.75[26]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 7,182[13]. - The largest shareholder, Dai Jianwei, holds 42.00% of the shares, totaling 57,113,219 shares[13]. Liabilities and Equity - The company's total liabilities were ¥81,272,014.66, down from ¥154,027,955.51, showing a significant reduction of about 47.3%[19]. - The equity attributable to shareholders increased slightly to ¥908,670,101.03 from ¥905,538,000.00, reflecting a marginal growth of 0.2%[19]. - The company reported a decrease in accounts payable from ¥32,498,762.59 to ¥12,428,953.12, a reduction of about 61.8%[19]. Research and Development - Research and development expenses increased by 31.45% during the reporting period, indicating a focus on innovation[11]. - Research and development expenses increased to CNY 5,569,046.07, representing a rise of 31.5% from CNY 4,236,733.51 in the previous year[20]. - The company has ongoing investments in new technologies and product development, although specific figures were not disclosed in the report[16]. Future Outlook - Future outlook includes potential market expansion strategies, although detailed projections were not provided in the current report[16]. Other Financial Metrics - The basic earnings per share for Q1 2022 was ¥0.05, unchanged from the previous year[6]. - Basic and diluted earnings per share remained stable at CNY 0.05 for both Q1 2022 and Q1 2021[22]. - The company reported a significant increase in cash received from sales, totaling CNY 58,036,517.48, compared to CNY 32,586,433.49 in the same period last year[24]. - The company experienced a credit impairment loss of CNY -2,524,893.79, worsening from CNY -1,388,038.97 in Q1 2021[21]. - The impact of exchange rate changes on cash and cash equivalents was -$53,215.71[26].

Financial Performance - The company's operating revenue for Q3 2021 was ¥133,371,277.49, representing a year-on-year increase of 155.77%[5] - The net profit attributable to shareholders for Q3 2021 was ¥26,049,161.53, up 58.80% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2021 was ¥26,019,969.90, an increase of 89.29% year-on-year[5] - For the first three quarters of 2021, the total operating revenue reached ¥285,036,667.40, reflecting a growth of 60.35% compared to the same period last year[5] - The net profit attributable to shareholders for the first three quarters of 2021 was ¥77,811,695.98, which is a 31.79% increase year-on-year[5] - Operating profit for the first three quarters of 2021 was ¥91,338,382.34, compared to ¥75,545,868.75 in 2020, indicating an increase of about 20.9%[21] - Net profit attributable to shareholders of the parent company for the first three quarters of 2021 was ¥77,811,695.98, up from ¥59,040,696.18 in 2020, reflecting a growth of approximately 31.7%[22] Earnings Per Share - The basic earnings per share for Q3 2021 was ¥0.19, an increase of 18.75% compared to the previous quarter[6] - The diluted earnings per share for Q3 2021 was also ¥0.19, reflecting the same growth rate of 18.75%[6] - The basic earnings per share for the first three quarters of 2021 was ¥0.57, slightly down from ¥0.58 in the same period of 2020[22] Assets and Liabilities - Total assets at the end of Q3 2021 amounted to ¥1,071,861,212.13, representing a 7.47% increase from the end of the previous year[6] - The equity attributable to shareholders at the end of Q3 2021 was ¥861,718,472.81, which is a 5.97% increase compared to the end of the previous year[6] - Current assets totaled RMB 824,013,504.61, slightly up from RMB 822,220,361.70 year-over-year[16] - Non-current assets increased to RMB 247,847,707.52 from RMB 175,183,711.05, representing a growth of approximately 41.4%[17] - Total liabilities reached RMB 142,896,849.50, compared to RMB 119,788,274.83 in the previous year, indicating an increase of about 19.3%[17] - The total assets of the company amounted to ¥1,071,861,212.13, an increase from ¥997,404,072.75 in the previous year, indicating a growth of about 7.4%[18] - The company's total equity reached ¥928,964,362.63, up from ¥877,615,797.92, reflecting an increase of approximately 5.8%[18] Cash Flow - The company reported a net cash flow from operating activities of ¥21,149,578.87 for the first three quarters of 2021, compared to ¥18,138,567.14 in the same period of 2020, showing an increase of about 11.1%[24] - The net cash flow from investing activities was -$182.35 million, compared to -$43.44 million in the previous period[25] - The total cash outflow from investing activities amounted to $302.74 million, with $250 million specifically for investment payments[25] - The net cash flow from financing activities was -$35.63 million, with cash inflow from borrowings at $33.72 million[25] - The company distributed dividends and interest payments totaling $27.82 million[25] - The net increase in cash and cash equivalents was -$197.03 million, contrasting with an increase of $8.49 million in the previous period[25] - The ending balance of cash and cash equivalents stood at $362.85 million, down from $559.88 million at the beginning of the period[25] Research and Development - Research and development expenses for the first three quarters of 2021 totaled ¥16,082,970.74, compared to ¥10,283,807.81 in 2020, marking a rise of approximately 56.5%[21] Other Information - The company has not reported any new product launches or technological advancements during this quarter[14] - There are no significant mergers or acquisitions reported in the current quarter[14] - The company did not apply the new leasing standards starting from 2021[25]